vs
Amphastar Pharmaceuticals, Inc.（AMPH）とTraeger, Inc.（COOK）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $145.4M、Traeger, Inc.の約1.3倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -11.8%、差は25.2%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -13.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $14.2M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs 0.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Traeger, Inc.は高品質な木質ペレットグリル、関連アクセサリー、専用木質ペレット燃料を設計・製造・販売する企業です。主に北米、欧州、オーストラリアを市場とし、小売パートナーと直販ルートを通じて一般家庭や飲食店顧客に製品を提供しています。
AMPH vs COOK — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $145.4M |
| 純利益 | $24.4M | $-17.2M |
| 粗利率 | 46.8% | 37.4% |
| 営業利益率 | 19.4% | -8.0% |
| 純利益率 | 13.3% | -11.8% |
| 売上前年比 | -1.8% | -13.8% |
| 純利益前年比 | -35.7% | -147.2% |
| EPS（希薄化後） | $0.51 | $-0.13 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $145.4M | ||
| Q3 25 | $191.8M | $125.4M | ||
| Q2 25 | $174.4M | $145.5M | ||
| Q1 25 | $170.5M | $143.3M | ||
| Q4 24 | $186.5M | $168.6M | ||
| Q3 24 | $191.2M | $122.0M | ||
| Q2 24 | $182.4M | $168.5M | ||
| Q1 24 | $171.8M | $144.9M |
| Q4 25 | $24.4M | $-17.2M | ||
| Q3 25 | $17.4M | $-89.8M | ||
| Q2 25 | $31.0M | $-7.4M | ||
| Q1 25 | $25.3M | $-778.0K | ||
| Q4 24 | $38.0M | $-7.0M | ||
| Q3 24 | $40.4M | $-19.8M | ||
| Q2 24 | $37.9M | $-2.6M | ||
| Q1 24 | $43.2M | $-4.7M |
| Q4 25 | 46.8% | 37.4% | ||
| Q3 25 | 51.4% | 38.7% | ||
| Q2 25 | 49.6% | 39.2% | ||
| Q1 25 | 50.0% | 41.5% | ||
| Q4 24 | 46.5% | 40.9% | ||
| Q3 24 | 53.3% | 42.3% | ||
| Q2 24 | 52.2% | 42.9% | ||
| Q1 24 | 52.4% | 43.2% |
| Q4 25 | 19.4% | -8.0% | ||
| Q3 25 | 13.2% | -66.5% | ||
| Q2 25 | 24.2% | -4.2% | ||
| Q1 25 | 21.9% | 2.4% | ||
| Q4 24 | 24.2% | -0.1% | ||
| Q3 24 | 29.8% | -6.1% | ||
| Q2 24 | 30.3% | 2.8% | ||
| Q1 24 | 27.9% | -0.1% |
| Q4 25 | 13.3% | -11.8% | ||
| Q3 25 | 9.0% | -71.6% | ||
| Q2 25 | 17.8% | -5.1% | ||
| Q1 25 | 14.8% | -0.5% | ||
| Q4 24 | 20.4% | -4.1% | ||
| Q3 24 | 21.1% | -16.2% | ||
| Q2 24 | 20.8% | -1.5% | ||
| Q1 24 | 25.1% | -3.2% |
| Q4 25 | $0.51 | $-0.13 | ||
| Q3 25 | $0.37 | $-0.67 | ||
| Q2 25 | $0.64 | $-0.06 | ||
| Q1 25 | $0.51 | $-0.01 | ||
| Q4 24 | $0.74 | $-0.06 | ||
| Q3 24 | $0.78 | $-0.15 | ||
| Q2 24 | $0.73 | $-0.02 | ||
| Q1 24 | $0.81 | $-0.04 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $19.6M |
| 総負債低いほど良い | $608.7M | $403.3M |
| 株主資本純資産 | $788.8M | $170.8M |
| 総資産 | $1.6B | $676.0M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 2.36× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $19.6M | ||
| Q3 25 | $276.2M | $5.9M | ||
| Q2 25 | $231.8M | $10.3M | ||
| Q1 25 | $236.9M | $12.0M | ||
| Q4 24 | $221.6M | $15.0M | ||
| Q3 24 | $250.5M | $16.9M | ||
| Q2 24 | $217.8M | $18.0M | ||
| Q1 24 | $289.6M | $23.6M |
| Q4 25 | $608.7M | $403.3M | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $403.6M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $170.8M | ||
| Q3 25 | $776.7M | $186.1M | ||
| Q2 25 | $757.5M | $274.2M | ||
| Q1 25 | $751.3M | $279.6M | ||
| Q4 24 | $732.3M | $276.4M | ||
| Q3 24 | $727.7M | $279.8M | ||
| Q2 24 | $713.3M | $297.3M | ||
| Q1 24 | $672.4M | $294.6M |
| Q4 25 | $1.6B | $676.0M | ||
| Q3 25 | $1.7B | $689.6M | ||
| Q2 25 | $1.6B | $780.6M | ||
| Q1 25 | $1.6B | $825.6M | ||
| Q4 24 | $1.6B | $830.7M | ||
| Q3 24 | $1.5B | $818.1M | ||
| Q2 24 | $1.5B | $842.4M | ||
| Q1 24 | $1.6B | $862.1M |
| Q4 25 | 0.77× | 2.36× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 1.46× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $15.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $14.2M |
| FCFマージンFCF / 売上 | 13.4% | 9.8% |
| 設備投資強度設備投資 / 売上 | 4.5% | 0.9% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $13.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $15.5M | ||
| Q3 25 | $52.6M | $7.6M | ||
| Q2 25 | $35.6M | $18.3M | ||
| Q1 25 | $35.1M | $-20.8M | ||
| Q4 24 | $29.0M | $7.5M | ||
| Q3 24 | $60.0M | $15.1M | ||
| Q2 24 | $69.1M | $13.9M | ||
| Q1 24 | $55.3M | $-12.6M |
| Q4 25 | $24.6M | $14.2M | ||
| Q3 25 | $47.2M | $6.4M | ||
| Q2 25 | $25.0M | $15.7M | ||
| Q1 25 | $24.4M | $-22.7M | ||
| Q4 24 | $16.6M | $5.5M | ||
| Q3 24 | $46.2M | $12.8M | ||
| Q2 24 | $63.1M | $11.8M | ||
| Q1 24 | $46.5M | $-18.3M |
| Q4 25 | 13.4% | 9.8% | ||
| Q3 25 | 24.6% | 5.1% | ||
| Q2 25 | 14.3% | 10.8% | ||
| Q1 25 | 14.3% | -15.8% | ||
| Q4 24 | 8.9% | 3.3% | ||
| Q3 24 | 24.1% | 10.5% | ||
| Q2 24 | 34.6% | 7.0% | ||
| Q1 24 | 27.1% | -12.6% |
| Q4 25 | 4.5% | 0.9% | ||
| Q3 25 | 2.8% | 0.9% | ||
| Q2 25 | 6.1% | 1.8% | ||
| Q1 25 | 6.3% | 1.3% | ||
| Q4 24 | 6.7% | 1.2% | ||
| Q3 24 | 7.2% | 1.9% | ||
| Q2 24 | 3.3% | 1.2% | ||
| Q1 24 | 5.1% | 3.9% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
COOK
| Grills | $60.6M | 42% |
| Accessories | $49.2M | 34% |
| Consumables | $35.5M | 24% |
